# A Single and Repeat Dose Trial in Participants With Hepatic Impairment

> **NCT05009680** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Galecto Biotech AB** · enrollment: 54 (estimated)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** GB1211
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05009680
- **Lead sponsor:** Galecto Biotech AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-09
- **Primary completion:** 2022-07-18
- **Final completion:** 2023-07-04
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2023-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05009680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05009680, "A Single and Repeat Dose Trial in Participants With Hepatic Impairment". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05009680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*